Graves' Disease Induced by Epstein-Barr Virus Lytic Reactivation

Status Not yet recruiting

Clinical Trial Summary

Previous studies have proved that the lytic reactivation of latent Epstein-Barr virus (EBV) was significantly associated with the onset of Graves'disease (GD), however, the morbidity of GD and recurrence rate of hyperthyroidism after antithyroid drugs treatment due to lytic reactivation of EBV is not understood. We will recruit patients with newly diagnosed GD and recurrence of hyperthyroidism after antithyroid drugs treatment. In order to confirm lytic reactivation of EBV, the number of EBV DNA copies，mRNA and protein expression of immediate-early, early and late lytic EBV genes，EBV +TRAb+cells will be tested. The proportion of lytic reactivation of EBV in newly diagnosed GD and recurrence of hyperthyroidism was evaluated.

Clinical Trial Description

The lytic reactivation of latent EBV play importment roles in development of GD and recurrence rate of hyperthyroidism. The aim of this study is to evaluate the proportion of lytic reactivation of EBV in newly diagnosed GD and recurrence of hyperthyroidism. All patients satisfied the diagnostic criteria for GD. The diagnotic remission of hyperthyroidism was included of clinical symptoms and elevated FT3 and FT4, the patients who have been received antithyroid drugs (methimazole or propylthiouracil) titration treatment for 18 or more months and of antithyroid drugs titration treatment and withdrawal antithyroid drugs at least 3 months. The evaluation of lytic reactivation of latent EBV including EBV DNA copies，mRNA and protein expression of immediate-early, early and late lytic genes，and EBV +TRAb+cells. The EBV DNA copies was tested with PCR, mRNA and protein expression of immediate-early, early and late lytic EBV genes were analysed with RT-qPCR or Western blot and EBV +TRAb+cells were evaluated with flow cytometry. All statistical tests were performed using GraphPad Prism V8.0. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06426758
Study type	Observational
Source	Nanjing Medical University
Contact	Xiao-Ming Mao, MD.
Phone	+86-18951670295
Email	maoxming@163.com
Status	Not yet recruiting
Phase
Start date	May 30, 2024
Completion date	September 1, 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05774535` - Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
Completed	`NCT02973802` - ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy	Phase 1
Completed	`NCT02491567` - DNA Methylation and Autoimmune Thyroid Diseases
Terminated	`NCT01320813` - Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy	N/A
Completed	`NCT00432146` - Effect of Lugol's Solution in the Patients With Graves' Disease	N/A
Recruiting	`NCT06081439` - Validating Immunological Markers Associated With Mental Fatigue in Graves' Disease
Not yet recruiting	`NCT06327828` - Methimazole in Graves' Disease - Comparing the Computer-aided Treatment DigiThy Versus Usual Care	N/A
Recruiting	`NCT05635266` - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed	`NCT01727973` - Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy	Phase 1/Phase 2
Active, not recruiting	`NCT04135573` - The Relationship Between NK Cell and Graves' Disease
Recruiting	`NCT06134219` - Course for Brain Fatigue After Graves' Disease Controlled Study	N/A
Completed	`NCT04239521` - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Recruiting	`NCT05678374` - Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
Completed	`NCT03009357` - Clinical Application of Pulse Rate-monitoring Activity Trackers in Thyrotoxicosis
Recruiting	`NCT05510609` - Three-dimensional Ultrasonography Thyroid Volume Measurement.	N/A
Recruiting	`NCT05907668` - A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease	Phase 2
Recruiting	`NCT06275373` - The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Recruiting	`NCT03303053` - Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism	Phase 3
Recruiting	`NCT05461820` - Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease	Phase 4
Recruiting	`NCT06309316` - The Impact of Person Centred Care (PCC) in Grave's Disease	N/A